- Home
- KWR vs DNLI Comparison
KWR vs DNLI Comparison
Compare KWR & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KWR
- DNLI
- Stock Information
- Founded
- KWR 1918
- DNLI 2013
- Country
- KWR United States
- DNLI United States
- Employees
- KWR N/A
- DNLI N/A
- Industry
- KWR Major Chemicals
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KWR Industrials
- DNLI Health Care
- Exchange
- KWR Nasdaq
- DNLI Nasdaq
- Market Cap
- KWR 1.8B
- DNLI 1.9B
- IPO Year
- KWR 1985
- DNLI 2017
- Fundamental
- Price
- KWR $103.37
- DNLI $14.37
- Analyst Decision
- KWR Strong Buy
- DNLI Strong Buy
- Analyst Count
- KWR 4
- DNLI 15
- Target Price
- KWR $157.75
- DNLI $33.92
- AVG Volume (30 Days)
- KWR 151.4K
- DNLI 1.4M
- Earning Date
- KWR 05-01-2025
- DNLI 05-06-2025
- Dividend Yield
- KWR 1.87%
- DNLI N/A
- EPS Growth
- KWR N/A
- DNLI N/A
- EPS
- KWR 5.29
- DNLI N/A
- Revenue
- KWR $1,812,841,000.00
- DNLI N/A
- Revenue This Year
- KWR $3.06
- DNLI N/A
- Revenue Next Year
- KWR $5.01
- DNLI $384.25
- P/E Ratio
- KWR $19.63
- DNLI N/A
- Revenue Growth
- KWR N/A
- DNLI N/A
- 52 Week Low
- KWR $95.91
- DNLI $10.57
- 52 Week High
- KWR $197.03
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- KWR 42.34
- DNLI 46.97
- Support Level
- KWR $99.18
- DNLI $13.36
- Resistance Level
- KWR $107.00
- DNLI $16.97
- Average True Range (ATR)
- KWR 3.93
- DNLI 0.95
- MACD
- KWR 0.90
- DNLI -0.06
- Stochastic Oscillator
- KWR 41.57
- DNLI 28.08
About KWR Quaker Houghton
Quaker Houghton manufactures and sells a variety of industrial process fluids. The product portfolio of the company includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids and surface treatment chemicals. The geographic segments of the company include America, EMEA, Asia/Pacific, and Global Specialty Businesses. The majority of the revenue is earned from America.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.